Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — Shareholder Meeting (July 2021)
41 slides from Anteris Technologies Global's shareholder meeting presentation, Jul 15, 2021
Slide 1: AGM Chairman's Address and CEO Presentation
ASX ANNOUNCEMENT For personal use only 15 July 2021 ANNUAL GENERAL MEETING CHAIRMAN’S ADRESS AND CHIEF EXECUTIVE OFFICER PRESENTATION BRISBANE, 15 July 2021: Anteris Technologies Ltd (ASX: AVR) is pleased to provide the attached Chairman’s Address and Chief Executive Officer Presentation to the Annu
Slide 2: Chairman's Address
CHAIRMAN’S ADRESS Good morning everyone! My name is John Seaberg and I’m the Chairman of Anteris Technologies For personal use only Ltd. On behalf of the Board and the Management Team a very warm welcome to the 2021 Annual General Meeting. Before turning this over to Wayne Paterson, I’d like to offe
Slide 3: Chairman's Address (continued)
Which brings me to the end of my comments. You’ve all heard the story about the sculptor who had made a wonderful sculpture of a bear. The person buying the sculpture asked him how did he take a solid block of granite and turn it into such a beautiful powerful sculpture. Its easy he said, I just car
Slide 4: Annual General Meeting CEO Presentation
For personal use only Anteris Technologies Ltd Annual General Meeting 2020 CEO Presentation 15 July 2021
Slide 5: Disclaimer
Disclaimer For personal use only This presentation contains general information which is current as of 15 July 2021. It is information given in summary form and does not purport to be complete. Information in this presentation is not intended to be relied upon as advice to investors or potential inv
Slide 6: DurAVR for lifetime management of Aortic Stenosis patients
For personal use only DurAVR™ for lifetime management of Aortic Stenosis patients www.anteristech.com | Follow us @anteristech Copyright Anteris Technologies Ltd 2021
Slide 7: 2020 was an incredible year of progress, milestones and value creation
2020 was an incredible year of progress, milestones and value creation For personal use only 2020 is the year DurAVR™ moved from concept to product • Commenced FIH DurAVR™ study • “Best Innovation” awarded at PCR London Valves • Developed unique commissure attachment method to enhance stress reducti
Slide 8: Financial highlights 2020
Financial highlights 2020 For personal use only UP TO $11.9M $20M 36% Sales revenue and Funding package Reduction in Selling, other income announced in early General and Administrative 2021 expenses compared to prior year $2.3M 43.1 Capital raised in Total full time 2020 Equivalent staff
Slide 9: FY20 Financial information
FY20 Financial information For personal use only $ million FY2019 FY2020 FY2020 budget actual • LeMaitre transaction in 2019 brought ADAPT® revenue 10.2 6.8 6.2 forward revenue/capital as well as Infusion revenue 6.9 - 0.9 reduced SG&A 17.1 6.8 7.1 • Ongoing 20% margin over costs Gain on business di
Slide 10: Breakdown of operational results
Breakdown of operational results For personal use only Overall results $15.3M loss Research & Development $11.1M Corporate & Operational $4.2M • DurAVRTM valve development • Regulatory and Medical program • Capital raising costs • First-in-human trials • Company compliance costs • Design of the TAVR
Slide 11: Patent applications increased dramatically in 2020
Due to the pace of development in 2020 patent applications increased dramatically For personal use only In 2020, Anteris: - 38 new applications throughout the world in 7 different patent families Filed - Received 2 issued patents (5% of pending applications) - Received 1 notice of allowance in the U
Slide 12: Progress since code red
Progress since code red - Our ability to pivot has been key For personal use only Code Red Objectives Where we’re at today • Manufacturing pass rates to rise from a low of 22% to 75+% • Manufacturing pass rates have been consistently >70% since FY17 with pass rates of 76% in FY20 • 250% increase in
Slide 13: Equity capital raised
Equity capital raised For personal use only $40.0 M $35.8 M $35.4 M $35.0 M $30.0 M $25.0 M $20.0 M $18.4 M $18.3 M $15.0 M $14.1 M $10.0 M $5.0 M $3.9 M $1.1 M $0.0 M $0.0 M $0.0 M 2013 2014 2015 2016 2017 2018 2019 2020 2021
Slide 14: Capital raised through debt & equity
Capital raised through debt & equity For personal use only $40.0 M Equity capital raised $5.0 M Borrowings $35.0 M LeMaitre & Infusion $30.0 M $25.0 M $20.0 M $35.8 M $35.4 M $15.0 M $28.2 M $10.0 M $18.4 M $18.3 M $14.1 M $5.0 M $5.0 M $5.0 M $1.2 M $3.9 M $1.0 M $1.1 M $0.0 M 2013 2014 2015 2016 2
Slide 15: AVR share price and trading volumes
AVR share price and trading volumes For personal use only Small volumes and price declines Strong volumes and price growth Source: www.marketindex.com.au/asx/avr
Slide 16: What is this disease and why are we competitive?
For personal use only What is this disease and why are we competitive?
Slide 17: Aortic Stenosis has a high mortality rate if left untreated
Aortic Stenosis has a high mortality rate within 2-3 years if left untreatedvv For personal use only • It is estimated that 1 in 8 elderly Australians has Aortic Stenosis (AS). • Calcific Aortic Stenosis is the most common cause of Aortic Stenosis. • While up to 1.5 million people in the US suffer f
Slide 18: Aortic stenosis is a disease of calcification
Aortic stenosis is a disease of calcification For personal use only Calcium deposits cause a narrowing of the valve opening and an increase in pressure Calcium build up in valve with stenosis
Slide 19: Anteris is focused on tissue science and valve technology
Anteris is focused on tissue science and valve technology For personal use only Three reasons Anteris will be the market leader in the future DurAVR™ is first and only 3D single- 1 piece aortic valve Clinically proven ADAPT® anti-calcification 2 treatment ACELLULARIZE DETOXIFY CROSSLINK DurAVR™ THV
Slide 20: What the experts are saying
For personal use only What the experts are saying
Slide 21: Experts need a TAVR with better hemodynamics and durability
Experts need a TAVR with better Hemodynamics & Durability For personal use only 5min
Slide 22: World class TAVR focused advisory board
Anteris is supported by a world class TAVR focused advisory board For personal use only Gorav Ailawadi, MD Vinayak Bapat, MD Samir Kapadia, MD University of Virginia Health System New York-Presbyterian/Columbia Medical Cleveland Clinic Charlottesville, VA Center, New York, NY Cleveland, OH Susheel K
Slide 23: Younger patients need new solutions
Younger patients need new solutions For personal use only Younger patients need longer lasting next generation valve technology Patient Age Key Considerations Younger patients now eligible Guidelines What Life Expectancy TAVR as class(I) for ages 65-80 Does this Mean? Exercise Capacity Indications:
Slide 24: Current solutions attempt to address key areas
Current solutions attempt to address 4 key areas Current TAVR devices For personal use only Current products fall short in two critical areas Predictable Optimal Low Incidence of Procedure Hemodynamic Durability Complications Performance Competitor products leave the patient in “mild” Competitor pro
Slide 25: DurAVR THV satisfies all key areas
DurAVR THV satisfies all 4 key areas ™ Current TAVR devices For personal use only ComASUR™ delivery system is Better hemodynamics at rest DurAVR’s™ 3D uni-body design has more predictable with and during increased cardiac greater structural integrity + ADAPT® commissural alignment output (exercise)
Slide 26: The Australian perspective
For personal use only The Australian perspective
Slide 27: For personal use only
For personal use only
Slide 28: The Competitors
For personal use only The Competitors
Slide 29: TAVR Market Shares by Region (US & EU5)
TAVR Market Shares by Region (US & EU5) For personal use only
Slide 30: DurAVR better by design
DurAVR™ better by design For personal use only Effective Orifice Area 3.0cm2 1.5 to 3 cm2 1.0 to 1.5 cm2 <1.0 cm2 (EOA) cm2 Mean Gradient 5 mmHg <20 mmHg 20-40 mmHg >40 mmHg mmHg Mean Gradient EOA cm2 mmHg *Sapien 3 19-16 mmHg 1.22-1.66 cm2 *Corevalve 8.27-14.43 mmHg 1.12-2.15 cm2 **DurAVR™ 5-7 mmHg
Slide 31: DurAVR THV System meets the needs of patients and physicians
DurAVR™ THV System meets the needs of Patients and Physicians For personal use only PROVEN ADAPT® TISSUE PLATFORM BALLOON 3D SHAPED EXPANDABLE, VALVE LARGE CELL UNIBODY SUPRA- CONSTRUCT ANNULAR COMMISSURAL PVL SOLUTION ALIGNMENT BALLOON SELF EXPANDABLE EXPANDING MORE EFFICIENT MANUFACTURING PROCESSE
Slide 32: DurAVR THV System designed to go the distance
DurAVR™ THV System designed to go the distance For personal use only BALLOON SELF EXPANDABLE EXPANDING Predictable procedure Only 3D “unibody” valve Predictable procedure Larger EOA with superior hemodynamics Normal hemodynamics Low pacemaker rate ® Built with ADAPT proven anti-calcification tissue
Slide 33: The road ahead
For personal use only The road ahead
Slide 34: 2021/2022 will be the most transformational in the company's history
2021/2022 will be the most transformational in the company’s history For personal use only Discussions around DOCTORS & PATIENTS NEEDS: developing a Self Balloon Expandable with the Expanding or Balloon hemodynamics benefits of a Self- Expanding valve expandable heart valve Creation of Anteris’ CHOI
Slide 35: Anteris pipeline poised to drive major catalysts
Anteris pipeline is poised to drive major catalysts from 2021 For personal use only Product Development Pre-Clinical Clinical Registration US (EFS, Pivotal), DurAVR™ THV Preclinical Studies EU (CE) Valve Replacement DurAVR™ SHV Programs FIH (stentless Aortic) DurAVR™ SHV POC (stented Aortic) DurAVR™
Slide 36: Shareholder questions
Shareholder questions Questions For personal use only • When will you get a partnership? • When can we get the licence fee deal implied in the MST report? • If you need to go it alone how will you secure capital for this? • When raising capital why do retail holders not get an option to participate
Slide 37: A great team in the right locations
A great team in the right locations Exceptional individuals doing exceptional things For personal use only Biologics Manufacturing / R&D Innovation Centre & Corporate HQ Strategic Hub in Europe (Malaga, Australia) (Minneapolis, USA) (Geneva, Switzerland) Finance & IT Team (Brisbane, Australia)
Slide 38: Conclusions - We are now in the window of certainty
Conclusions - We are now in the window of certainty For personal use only It’s been an incredible year of progress and achievement – we now have a very competitive product ready to enter its registration studies This is no longer a discussion about will we be able to develop a product, or if it’s co
Slide 39: Mary is living with Aortic Stenosis
Mary is 68 years old and living with Aortic Stenosis For personal use only • Her stenosis has become so severe, she is no longer able to do things she loves, such as going for long walks with her grandkids • Her doctor says she needs a new valve soon – otherwise she may not live too much longer • Re
Slide 40: Anteris: An Australian Global Health Care Company
Anteris An Australian Global Health Care Company For personal use only
Slide 41: Innovation to support life's journey is at the heart of our story
For personal use only Innovation to support life’s journey is at the heart of our story… North America Europe Australia 860 Blue Gentian Road, Suite 340 Rte de Pre-Bois 20, PO BOX 1877 Toowong Tower Level 3, 9 Sherwood Rd Eagan MN 55121 1215 Geneva 15 Toowong QLD 4066
Anteris Technologies — Shareholder Meeting (July 2021) on 6ix